• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of proteasome inhibitor sensitivity determination mechanism in AL amyloidosis

Research Project

Project/Area Number 18K07322
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionShinshu University

Principal Investigator

Katoh Nagaaki  信州大学, 学術研究院医学系(医学部附属病院), 准教授 (30570014)

Project Period (FY) 2018-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2022: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2021: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
KeywordsALアミロイドーシス / プロテアソーム阻害剤 / 免疫調整薬(IMIDs) / 治療感受性 / 形質細胞染色体異常
Outline of Final Research Achievements

Cases and samples were collected, and measurements and experiments were performed using the samples. Some results of the obtained clinical study (case study) part were reported in Shinshu Med J. 2022 70(1):29-38. It was suggested that treatment of patients with AL amyloidosis with a proteasome inhibitor-based chemotherapy regimen followed by a lenalidomide (immunomodulatory drug, IMIDs)-based chemotherapy regimen results in better outcomes than conventional treatment. The importance of sufficient reduction of the amyloid precursor protein (free light chain) concentration in the patient's blood by administering a proteasome inhibitor before performing lenalidomide-based regimen was suggested.

Academic Significance and Societal Importance of the Research Achievements

この研究の結果は、ALアミロイドーシス患者のより効果的な化学療法治療計画の策定に役立つ可能性がある。

Report

(6 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (1 results)

All 2022

All Journal Article (1 results) (of which Peer Reviewed: 1 results)

  • [Journal Article] Therapeutic Outcome of Lenalidomide-dexamethasone in Patients with Relapsed or Refractory Systemic Immunoglobulin Light Chain (AL) Amyloidosis: A Single-center Analysis and Review of the Literature.2022

    • Author(s)
      Ueno A, Katoh N, Ezawa N, Yoshinaga T, Yazaki M, Sekijima Y.
    • Journal Title

      Shinshu Med J

      Volume: 70 Pages: 29-38

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed

URL: 

Published: 2018-04-23   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi